Pharm-Rx Methotrexate USP

Product families

Other characteristics

Certifications & Compliance

United States Pharmacopeia (USP)

Markets

Healthcare & Pharma

Defination

Methotrexate contains NLT 98.0% and NMT 102.0% of methotrexate (C₂₀H₂₂N₈O₅), calculated on the anhydrous basis.

Technology

Pharmaceuticals & Nutraceuticals

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage Information

Preserve in tight, light-resistant containers.

USP Reference Standards

Methotrexate Methotrexate dimethylester hydrochloride; (S)-Dimethyl-2-(4-{[(2,4-diaminopteridin-6-yl)methyl] (methyl)amino}benzamido) pentanedioate hydrochloride. C₂₂H₂₆N₈O₅; Methotrexate related compound I; (S)-4-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl) amino}benzamido)-5-methoxy-5-oxopentanoic acid. C₂₁H₂₄N₈O₅ 468.47; USP Methotrexate RS USP Methotrexate Related Compound B RS (S)-2-{4-[(2,4-Diaminopteridin-6-yl)methylamino] benzamido}pentanedioic acid. C₁₉H₂₀N₈O₅ 440.42 USP; Methotrexate Related Compound C RS (S)-2-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl) methyl](methyl)amino}benzamido)pentanedioic acid. C₂₀H₂₁N₇O₆ 455.42; USP Methotrexate Related Compound E RS 4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino} benzoic acid, hemihydrochloride. C₁₅H₁₅N₇O₂ · 1⁄2HCl 343.56

Show in full

Certifications and Compliance

United States Pharmacopeia (USP)